TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00681538
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
Study: NCT00630812
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
Study: NCT04209777
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin capsules 500mg and metronidazole tablets 400mg antibiotics were used as an active comparator.
Study: NCT00692510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, oral, dose once daily, 7 days
Study: NCT00692510
Drug: Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix
Study: NCT01329029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT03578874
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO
Study: NCT00240318
Drug: Rosuvastatin calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00344123
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r..
Study: NCT01218438
Drug: Immune Globulin Subcutaneous (Human), 20% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infusion with IGSC, 20%
Study: NCT02786082
Drug: 20mg Azilsartan Tablets
Normalized name: azilsartan Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength: 20mg, oral administration 1 tablet/ day
Study: NCT02786082
Drug: 40mg Azilsartan Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength: 40mg, oral administration 1 tablet/ day
Study: NCT01327326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 1 Time Dose
Study: NCT00037635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
Study: NCT02918409
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00243412
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
Study: NCT03653403
Drug: IDP-126 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Component A
Study: NCT00678587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, once daily, oral
Study: NCT00243412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
Study: NCT02364167
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
Study: NCT00275119
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03574935
Drug: External Chinese medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~1. Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~2. Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~3. Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome.
Study: NCT03574935
Drug: External Western medicine
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear).
Study: NCT04729491
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500mg/day for 05 days
Study: NCT04729491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
Study: NCT02981277
Drug: Transcricoid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine delivery using Transcricoid Injection
Study: NCT02981277
Drug: Spray as you go
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine delivery using Spray as you go method
Study: NCT02671942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02860806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of matching placebo.
Study: NCT00655980
Drug: Vitamin B12 and folic acid
Normalized name: VITAMIN B12 AND FOLIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
Study: NCT01367262
Drug: LY2886721
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03240393
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Description: cMET GCN ≥ 6 cMET GCN ≥ 4 and \< 6 cMET mutations
Study: NCT01606761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
Study: NCT01606761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
Study: NCT02497157
Drug: Continuous intravenous infusion of fluorouracil (CIV 5-FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02497157
Drug: Levofolinate calcium (l-LV)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02415439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00993421
Drug: LY377604
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given daily, orally for 24 weeks
Study: NCT00993421
Drug: Placebo LY377604
Approvals — FDA: no, EMA: no, PMDA: no
Description: given daily, orally for 24 weeks
Study: NCT00936390
Drug: LHRH agonist (antagonist) therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix. The manufacturer's instructions should be followed. The first administration occurs with the start of anti-androgen treatment 8 weeks prior to the start of RT. The total duration of LHRH agonist (antagonist) therapy is 6 months.
Study: NCT02459574
Drug: Anti-Arrhythmic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 will be prescribed medication listed below:~Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.~You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed.
Study: NCT02940626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01015482
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil Infusion
Study: NCT05737173
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular knee injection
Study: NCT02626572
Drug: S47445 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
Study: NCT02626572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
Study: NCT02038673
Drug: ASP5878
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00751855
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
Study: NCT00751855
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00575952
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00710047
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: one single 10mg dose
Study: NCT03790176
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: see arm/group description. NO INTERVENTION IN STUDY GROUP B! PATIENTS OF GROUP B WILL RECEIVE CAZ/AVI INDEPENDENTLY FROM STUDY PARTICIPATION BASED ON DECISION OF THEIR TREATING PHYSICIAN
Study: NCT00628732
Drug: Cyclophosphamide and Topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
Study: NCT00006054
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006054
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00198445
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop in study eye every 12 hours for 14 days
Study: NCT00198445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in study eye every 12 hours for 14 days
Study: NCT00208312
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.14 mg/kg/min for 6 minutes, intravenous infusion
Study: NCT03553433
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indistinguishable tablets not containing apremilast, Placebo Oral Tablet
Study: NCT01290133
Drug: GW597599
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose IV infusion
Study: NCT01290133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose IV infusion
Study: NCT03054467
Drug: Caduet 10Mg-20Mg Tablet
Normalized name: Caduet 10mg-20mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
Study: NCT03054467
Drug: NorvasC® 10 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
Study: NCT00796601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablets (0 mg esreboxetine), once daily for 6 months
Study: NCT02779192
Drug: SPI-1005 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
Study: NCT02779192
Drug: SPI-1005 400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
Study: NCT02779192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
Study: NCT00389740
Drug: MK0217, /Duration of Treatment : 12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03745196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control
Study: NCT00832546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00832546
Drug: Oral NGX426 (Powder in solution)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03414008
Drug: Matching placebo: Tartaric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT00669916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single infusion of placebo
Study: NCT01054820
Drug: FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
Study: NCT01788306
Drug: OOPEN+BBCC
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
Study: NCT02624973
Drug: Neoadjuvant docetaxel + cyclophosphamide
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02624973
Drug: Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02624973
Drug: Adjuvant Epirubicin+ Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02605954
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg FDC tablets administered orally once daily
Study: NCT02605954
Drug: ABC/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600/300 mg tablets administered orally once daily
Study: NCT02605954
Drug: Third Antiretroviral Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third antiretroviral agents could include one of the following:~* ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC~* DRV+COBI or DRV/COBI FDC~* darunavir (DRV; Prezista®) + RTV~* lopinavir/ritonavir (LPV/r; Kaletra®)~* atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)~* efavirenz (EFV; Sustiva®)~* etravirine (ETR; Intelence®)~* nevirapine (NVP; Viramune®)~* rilpivirine (RPV; Edurant®)~* dolutegravir (DTG; Tivicay®)~* raltegravir (RAL; Isentress®)~* fosamprenavir (FPV; Lexiva®) + RTV~* saquinavir (SQV; Invirase®) + RTV~* ATV (no booster)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG
Study: NCT04609254
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg Ibuprofen (İntrafen 400 mg vial- Gen-İstanbul) intravenous (IV) was given 69 patients, which determined to be applied as a group.
Study: NCT02301143
Drug: Chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02301143
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00803647
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
Study: NCT02385448
Drug: Microgynon
Approvals — FDA: no, EMA: no, PMDA: no
Description: The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
Study: NCT02148250
Drug: U-500 insulin, 100 syringe units
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are randomized to receive 100 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
Study: NCT02148250
Drug: U-500 insulin, 200 syringe units
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are randomized to receive 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
Study: NCT02553330
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00373334
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02896855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to pertuzumab was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
Study: NCT02370602
Drug: [^11C]T-773
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[\^11C\]T-773 IV solution
Study: NCT00354523
Drug: Capecitabine (Xeloda)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting Dose 500 mg/m\^2 twice a day Days 1-14 of 21 Day Cycle.
Study: NCT01571362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo, divided into symmetric doses and administered twice daily
Study: NCT04547894
Drug: ASC09F
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days.
Study: NCT02529774
Drug: Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic Artery Infusion for four cycles:~Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion~In combination with Systemic Chemotherapy CapeOX for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1
Study: NCT02529774
Drug: Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic Chemotherapy CapeOX alone for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1
Study: NCT03222518
Drug: paracetamol-NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 identical pills of paracetamol ith a preconised dose of 1 pill 3 times per day over 7 days period+14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
Study: NCT04501679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received matching placebo as SC injection.
Study: NCT03417687
Drug: 129Xe MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of pulmonary function
Study: NCT03417687
Drug: 133 Xe scintigraphy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of pulmonary function
Study: NCT04137380
Drug: Placebo - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04137380
Drug: Placebo - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02777151
Drug: REGN3470-3471-3479
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02777151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03667053
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for dasiglucagon
Study: NCT00041132
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 on days 2-4 of cycles 1,3,5,7
Study: NCT01621217
Drug: 5-Fluoruracil
Normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be given intravenously twice together with Mitomycin C during study treatment
Study: NCT03455972
Drug: Immunomodulatory drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy
Study: NCT00990223
Drug: Eplerenone or Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 100 mg or Placebo, daily for 10 days.
Study: NCT00041132
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16.6 mg/m\^2/day for days 5-7 of cycles 1,3,5,7
Study: NCT00041132
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 170 mg over days 3-5 of cycles 2,4,6,8
Study: NCT00041132
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 over days 2-3 of cycles 2,4,6,8
Study: NCT02907021
Drug: standard-of-care treatments for LV impairment
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
Study: NCT03997851
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acetaminophen gel
Study: NCT02073084
Drug: K-877 Low Dose
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 Low Dose
Study: NCT02073084
Drug: K-877 High Dose
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 High Dose